Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 66 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KXnVLPzJiaB?= NYLRNWRUTE2VTx?= NEi1[nhKSzVyPUCuNFAxODdizszN MYKxO|k2PjB6MB?=
K562 NFHWPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LlO|czKGh? NHTvSFZFVVOR MlXvTWM2OD1yLkCwNUDPxE1? NFPkNmoyPzl3NkC4NC=>
M07e MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6wN5M4OiCq NH3FcVBFVVOR M2\iSWlEPTB;MD6wNFEzKM7:TR?= M1nwTlE4QTV4MEiw
ALL3 MXfDfZRwfG:6aXOgRZN{[Xl? MXuwMlHPxE1? NGPCT|E4OiCq MlzvSG1UVw>? NVX0fZM1UUN3ME2wMlAxODRizszN MknINVk5QDl3NEC=
CML NG\kdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M371eFIxKG2rbh?= MVzEUXNQ M1TkW2lEPTB;MD6wNFEh|ryP MkHNNVkzOTlyMU[=
BA/F3 M2nMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHCVlM4OiCq MlzWSG1UVw>? NIP1VZNKSzVyPU[uOVg6KM7:TR?= NUj2dW5{OjNyOEi2OFQ>
BA/F3 NYHXNohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLSeHB2PzJiaB?= M3XSZ2ROW09? MlnBTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MUWyN|A5QDZ2NB?=
BA/F3 NUX3d45UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni2O|IhcA>? NHPwfVRFVVOR MoPXTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? M{LydlI{ODh6NkS0
BA/F3 NF7QVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYm3NkBp M4i2NGROW09? NFTr[XdKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= MVmyN|A5QDZ2NB?=
BA/F3 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHMO|IhcA>? MUTEUXNQ M33wS2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP NIfC[44zOzNyMUewNy=>
BA/F3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK2R4ZjPzJiaB?= NIrE[IFFVVOR NInFNFJKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NUDldJRrOjN|MEG3NFM>
BA/F3 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\YO|IhcA>? NHu2fpVFVVOR MoPWTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? MXeyN|MxOTdyMx?=
BA/F3 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVm3NkBp Mk\pSG1UVw>? NWHtT|BDUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= M{L3XlI{OzBzN{Cz
BA/F3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEeVczKGh? MnHVSG1UVw>? NVz0XoJZUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= MUmyN|MxOTdyMx?=
BA/F3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq3NkBp MnrySG1UVw>? NHTQZ2pKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? NFy3d3MzOzNyMUewNy=>
BA/F3 NXvHTGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp MWPEUXNQ Mlf4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NWC0dZFQOjN|MEG3NFM>
BA/F3 NE\ZeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm3NkBp NFzaelRFVVOR NYOyVo41UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? M375SFI{OzBzN{Cz
BA/F3 M1Gw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q1UVczKGh? M3\1bmROW09? NGPKfolKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= Mn\rNlM{ODF5MEO=
T cell MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPjUZA4OiCq MoTMSG1UVw>? NGDScmZKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? NGHvUpQyPzF3NEWxNi=>
WiDr NIHnemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jKPVczKGh? M4ewO2ROW09? M3jPUWlEPTB;MD6wOVIh|ryP M1\lSFE2PjF3NUGy
PC3 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp NV\Wc4xUTE2VTx?= MmXsTWM2OD1yLkCwPVQh|ryP M37IWVE2PjF3NUGy
MDA-MB-231 M4fNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe3NkBp NVf2RmVRTE2VTx?= M2fmWGlEPTB;MD6wNVIh|ryP NIPBeGIyPTZzNUWxNi=>
Hs578T NVu4OGhRS3m2b4TvfIlkKEG|c3H5 NVzqXZJZPzJiaB?= NVvEW|dWTE2VTx?= NXzHe|NjT0l3ME2wMlA{KM7:TR?= NETiOZkzPDBzNUOyOy=>
HMEC MWTDfZRwfG:6aXOgRZN{[Xl? MUi3NkBp NF7EXpdFVVOR MYDHTVUxRTFwODFOwG0> NI\DepQzPDBzNUOyOy=>
DU145 NVfNblN7S3m2b4TvfIlkKEG|c3H5 NVLOfFlKPzJiaB?= NXjtSoFGTE2VTx?= M3TmbWdKPTB;MD6xOkDPxE1? Ml\jNlQxOTV|Mke=
U251 MVHDfZRwfG:6aXOgRZN{[Xl? MlXjO|IhcA>? NHXmPVZFVVOR MkfiS2k2OD1{LkixJO69VQ>? Mn\6NlQxOTV|Mke=
NCI60 NHm2WndEgXSxdH;4bYMhSXO|YYm= MnW1O|IhcA>? NXjNNFM5TE2VTx?= Mo\LS2k2OD13Lkeg{txO NGm0NHczPDBzNUOyOy=>
MALME-3M Mli2R5l1d3SxeHnjJGF{e2G7 MVq3NkBp MlvjSG1UVw>? NHHvNolIUTVyPU[uOlEh|ryP NEH3fWUzPDBzNUOyOy=>
KM12 MVvDfZRwfG:6aXOgRZN{[Xl? NX\VcYM5PzJiaB?= Ml[zSG1UVw>? NUnR[WhHT0l3ME23MlQ1KM7:TR?= MmXmNlQxOTV|Mke=
SW620 MWnDfZRwfG:6aXOgRZN{[Xl? M3zCUFczKGh? Mnr5SG1UVw>? NYXQWXE2T0l3ME24MlQ{KM7:TR?= NUSzcFNLOjRyMUWzNlc>
RXF 393NL NIOyOohEgXSxdH;4bYMhSXO|YYm= M{S4[VQh\GG7cx?= MXPEUXNQ NWHLeVh5UUN3ME2wMlAzOTdizszN MXKyN|I2OzB5NB?=
LXFA 983L M1GxNmN6fG:2b4jpZ{BCe3OjeR?= MknJOEBl[Xm| MXzEUXNQ MkTFTWM2OD1yLkC1OlUh|ryP M3rsPVI{OjV|MEe0
PRXF DU145 NUjaNYlES3m2b4TvfIlkKEG|c3H5 NWLQNlRuPCCmYYnz NXLJbWR3TE2VTx?= M3rXSWlEPTB;MD6wOlI{KM7:TR?= MYSyN|I2OzB5NB?=
PAXF 1657L NFXZd5ZEgXSxdH;4bYMhSXO|YYm= MkXFOEBl[Xm| M2CzOWROW09? MoTuTWM2OD1yLkGyNUDPxE1? M{fIN|I{OjV|MEe0
CXF 1103L NYjDOVRXS3m2b4TvfIlkKEG|c3H5 NHi1dW01KGSjeYO= M2HO[WROW09? NUewNoNrUUN3ME20MlM3KM7:TR?= M{f0XlI{OjV|MEe0
GXF251L NH7YN2lEgXSxdH;4bYMhSXO|YYm= NVPlOohvPCCmYYnz NHn6b|FFVVOR NUm4TpV6UUN3ME2yMlI2KM7:TR?= NFzKc|AzOzJ3M{C3OC=>
NCI-H23 NGDPUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vH[VczKGh? NX33[45OTE2VTx?= NXzzPZY1UUN3ME2yMlI4KM7:TR?= NIrOcpczOzV{MUCyNC=>
HCT116 M1y4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjXGs4OiCq MUfEUXNQ NWfnXFlwUUN3ME2yMlMh|ryP MX[yN|UzOTB{MB?=
MCF7 NWTtRW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDnOYI4OiCq MXrEUXNQ NWfqdopsUUN3ME2yMlU4KM7:TR?= NX[1W|c4OjN3MkGwNlA>
NCI-H460 M{i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zOS|czKGh? NVv5NWI{TE2VTx?= NV7Pcll7UUN3ME24Mlk6KM7:TR?= M4fvelI{PTJzMEKw
DLD1 NH[2bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jmZlczKGh? MYXEUXNQ MWPJR|UxRTRwNjFOwG0> MlLQNlM2Pjd7NkC=
NCI-H661 NX7PVI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPuO|IhcA>? MnPFSG1UVw>? M1fhVWlEPTB;Nz64JO69VQ>? MoS0NlM2Pjd7NkC=
A549 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj5eIFGPzJiaB?= NELHWoNFVVOR NV3GVIkxUUN3ME24MlIh|ryP MVGyN|U3Pzl4MB?=
U937 M3zHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nPVczKGh? M1\Xb2ROW09? M1[w[2lEPTB;MUKuNkDPxE1? NHfKRWczOzV4N{m2NC=>
HEK293 M1TpXWZ2dmO2aX;uJGF{e2G7 Ml;vNVDDqM7:TR?= M1fhUGROW09? MmfrTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= M2\qWVIzPzdyNkGw
HUVEC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLhNpRLOC5zNdMg{txO M4[2NVczKGh? M3qyfmROW09? NF;4VVhKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NHTHeFIzOjh3M{m5Ny=>
HUVEC MnLvSpVv[3Srb36gRZN{[Xl? MnrJNVXDqM7:TR?= Mmm0O|IhcA>? M4XxPWROW09? NYfzWpFEUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NWXsSIJpOjJ6NUO5PVM>
Plasmodium falciparum M1nFd2Z2dmO2aX;uJGF{e2G7 MlvJNVDDqM7:TR?= M1nRelE2KG2rbh?= NHTwUmNFVVOR MVrJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> MYiyOFU2ODN|MB?=
PC3 MXjGeY5kfGmxbjDBd5NigQ>? M1[3VlAvOSEQvF2= NYW1doxSPSCq NFrjT5BFVVOR NYTKU|dSUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MXuxPVQ3Ojl5NR?=
DU145 M3vzd2Z2dmO2aX;uJGF{e2G7 NELXVYIxNjFizszN NIHPXpE2KGh? MV7EUXNQ MYrJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MnnGNVk1PjJ7N{W=
PC3 MmPqT4lv[XOnIFHzd4F6 M2\BRVAvOSEQvF2= NGjwbW82KGh? MorrSG1UVw>? NXywNnFwUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MYSxPVQ3Ojl5NR?=
DU145 NUn5ZnZLU2mwYYPlJGF{e2G7 M33NXVAvOSEQvF2= NHv3PZo2KGh? NH32eZBFVVOR NGr4XnVKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MkDmNVk1PjJ7N{W=
PC3 MkDJT4lv[XOnIFHzd4F6 MXqwMlEh|ryP NGG3V2w2KGh? MlPkSG1UVw>? MV;Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M{S1WVE6PDZ{OUe1
DU145 MX\LbY5ie2ViQYPzZZk> MkDINE4yKM7:TR?= NFn3[Fc2KGh? MXXEUXNQ M{HPcmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NWj1PIxOOTl2NkK5O|U>
Huh7 NYfWNWw{SW62aY\pdoFtKEG|c3H5 Ml7GNk42KM7:TR?= M1:yeFQh\GG7cx?= MnrOSG1UVw>? NELhb45KdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= MXKxO|M3ODZ5Nh?=
C6/36 MlL3RY51cX[rcnHsJGF{e2G7 M4rIdVIvPSEQvF2= MV[0JIRigXN? NVjiUFRZTE2VTx?= NUHBPYV3UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NWT0R5NFOTd|NkC2O|Y>
U937 NGqxS2hHfW6ldHnvckBCe3OjeR?= NH7ROnIyKM7:TR?= NX\DWoJmOSCq M1POOmROW09? NYjQUXY4WmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NHrlPZMyPzZ6NEC5PS=>
U937 MlrSSpVv[3Srb36gRZN{[Xl? MWexJO69VQ>? MYexJIg> M3TMZmROW09? MnewVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> MnX6NVc3QDRyOUm=
murine mast cell NWC3V5NXTnWwY4Tpc44hSXO|YYm= NVvPVok3OSEQvF2= MWmyOEBp NIfzWJlFVVOR MlraTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? MXyxO|Y5PDB7OR?=
BV-173 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX5TWM2OD1yLkCwNFAxODFyOTFOwG0> NWqxdY5WW0GQR1XS
K-562 NXn1e3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjpVXhVUUN3ME2wMlAxODByMEK2OkDPxE1? MojlV2FPT0WU
BL-70 NFWzXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLRWlEPTB;MD6wNFAxODB6MkKg{txO NV\ONnV4W0GQR1XS
EM-2 NI[0eWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMECwNFAyODhizszN NHuwZmlUSU6JRWK=
LAMA-84 NFXPbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMECwNFA{OjFizszN NEXUflNUSU6JRWK=
MEG-01 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMECwNFA6QCEQvF2= NHPadZZUSU6JRWK=
EoL-1-cell NWP3XXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrUZoN{UUN3ME2wMlAxODBzM{Gg{txO MnfsV2FPT0WU
CTV-1 M1LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC0TWM2OD1yLkCwNFA1ODRizszN MnzyV2FPT0WU
TE-15 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDTWM2OD1yLkCwOVg6KM7:TR?= NXHNV2VbW0GQR1XS
NOS-1 NIPGbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEC2NVMh|ryP MWfTRW5ITVJ?
D-336MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEC2N{DPxE1? NIrNWmVUSU6JRWK=
LB1047-RCC M4rZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPZflNKSzVyPUCuNFA6QDlizszN MoDJV2FPT0WU
LB996-RCC MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDNUIRSUUN3ME2wMlAxQTlzIN88US=> M2ryWHNCVkeHUh?=
SW982 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEGxNVUh|ryP MoLHV2FPT0WU
TK10 NGLZc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEGxO|Qh|ryP NVrObldRW0GQR1XS
A704 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEG0PVEh|ryP M1juUXNCVkeHUh?=
TE-8 NXzsPYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEG1O|Yh|ryP M4XScXNCVkeHUh?=
DOHH-2 NHf0dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMc4VKSzVyPUCuNFE4OTlizszN NGfKfJlUSU6JRWK=
HOP-62 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD1yLkCxPFM1KM7:TR?= MoG5V2FPT0WU
TE-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEG4OlEh|ryP MV3TRW5ITVJ?
KGN Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEG5OFIh|ryP NXvVW4pnW0GQR1XS
NCI-H1648 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi4TWM2OD1yLkCyNFEyKM7:TR?= MYjTRW5ITVJ?
OS-RC-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEKwN{DPxE1? NHHwT|VUSU6JRWK=
GB-1 M4PmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEKxOVch|ryP Mnz2V2FPT0WU
RXF393 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QbmlEPTB;MD6wNlM2PyEQvF2= MlHIV2FPT0WU
LC-2-ad NXPrWYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjTcpNKSzVyPUCuNFI2QDZizszN NXLsSJBuW0GQR1XS
KS-1 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[5e2RvUUN3ME2wMlAzPzNizszN NFnqeGJUSU6JRWK=
ETK-1 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKxN45VUUN3ME2wMlAzQDN{IN88US=> MoP6V2FPT0WU
SW954 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnVRnNKSzVyPUCuNFI6OjdizszN NXzSfXBFW0GQR1XS
Becker MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LJPWlEPTB;MD6wN|AxOyEQvF2= MXHTRW5ITVJ?
MZ1-PC MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnqNVQxUUN3ME2wMlA{OTF7IN88US=> NIP0XnZUSU6JRWK=
ES6 M1XKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfiNHVKSzVyPUCuNFMyQTNizszN NGTBPYhUSU6JRWK=
KURAMOCHI NYn1bmF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjtXXpKSzVyPUCuNFM1QDdizszN M4T3S3NCVkeHUh?=
CGTH-W-1 M3noXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nmfWlEPTB;MD6wN|U1QCEQvF2= NInmSmdUSU6JRWK=
VA-ES-BJ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTI[VNKSzVyPUCuNFM6ODJizszN Ml60V2FPT0WU
LXF-289 NWfPV|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDOotKSzVyPUCuNFM6PTZizszN NF22O2NUSU6JRWK=
MPP-89 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\zVmNLUUN3ME2wMlA1ODR7IN88US=> MV;TRW5ITVJ?
SW872 M4fhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMESxOlEh|ryP MkHpV2FPT0WU
SNB75 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37k[GlEPTB;MD6wOFQ{PSEQvF2= M4jxSXNCVkeHUh?=
PSN1 NYTIZ3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrCTWM2OD1yLkC0OFc1KM7:TR?= M3i3XnNCVkeHUh?=
LB831-BLC M3nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LPfWlEPTB;MD6wOFYxQSEQvF2= NGn1WHBUSU6JRWK=
MFH-ino NELmO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nYWGlEPTB;MD6wOFczPCEQvF2= MniyV2FPT0WU
TGBC24TKB NF7HcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMES3OlEh|ryP MXPTRW5ITVJ?
A388 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLtSHJKSzVyPUCuNFUxQTVizszN NWDNSZJOW0GQR1XS
BB30-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PETmlEPTB;MD6wOVQ{PyEQvF2= MXHTRW5ITVJ?
GI-ME-N NWD0d2pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W0eGlEPTB;MD6wOlEyQCEQvF2= NYD6O4NrW0GQR1XS
TGBC1TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO0NolKSzVyPUCuNFYyPjRizszN MVXTRW5ITVJ?
TE-10 NVK1WpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwME[zOVch|ryP NGTQVppUSU6JRWK=
A498 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XEVmlEPTB;MD6wO|I5PCEQvF2= NGrZfHlUSU6JRWK=
TE-11 NXfDfFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKxeHhKSzVyPUCuNFc5PThizszN NVvXd4pJW0GQR1XS
BB65-RCC NVziVpNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3bFRKSzVyPUCuNFgzOjdizszN NY\ndFNnW0GQR1XS
C2BBe1 NI\BbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fHc2lEPTB;MD6wPFMxQCEQvF2= M2LheXNCVkeHUh?=
NCI-H747 NFLIb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nsZmlEPTB;MD6wPFM3OiEQvF2= NFuwTVVUSU6JRWK=
IST-MES1 M4[5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;QTpRKSzVyPUCuNFg2PTJizszN NUfGTFc1W0GQR1XS
KALS-1 M3rxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDTTWM2OD1yLkC5OFkh|ryP NFjROFhUSU6JRWK=
GCIY NY\N[lJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfJTWM2OD1yLkC5OlU3KM7:TR?= M1jwSXNCVkeHUh?=
RL95-2 M1TMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1frXWlEPTB;MD6xNFM5KM7:TR?= NHi3Z4lUSU6JRWK=
TE-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz0WoV4UUN3ME2wMlExPTRizszN NHfxNZNUSU6JRWK=
NCI-H1355 NHvVOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUGwNlgh|ryP NIf0ZnRUSU6JRWK=
SW962 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPsbI9jUUN3ME2wMlEyOjl{IN88US=> NYn0d|liW0GQR1XS
KLE M{WxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMUGzNVch|ryP NXXpfXJUW0GQR1XS
MC116 NWnjPWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXGTWM2OD1yLkGxOFEh|ryP M{XWcnNCVkeHUh?=
NMC-G1 NFzNOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMUG2NFYh|ryP MVPTRW5ITVJ?
KU812 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJfGRsUUN3ME2wMlEyQDh|IN88US=> NVPJRphtW0GQR1XS
COLO-829 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\nd45UUUN3ME2wMlEzOjF|IN88US=> MmnSV2FPT0WU
NTERA-S-cl-D1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljuTWM2OD1yLkGyNlg{KM7:TR?= NHHufIFUSU6JRWK=
IST-MEL1 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsbWlEPTB;MD6xN|Q2KM7:TR?= MVPTRW5ITVJ?
MLMA MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfnTWM2OD1yLkG0NFMzKM7:TR?= MVvTRW5ITVJ?
LS-123 M{H1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fYOmlEPTB;MD6xOFA3PCEQvF2= NInzV4lUSU6JRWK=
LB2518-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rWTGlEPTB;MD6xOFE3OiEQvF2= M2nMU3NCVkeHUh?=
NB69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOwdG11UUN3ME2wMlE1PDN4IN88US=> MWnTRW5ITVJ?
8-MG-BA M1O2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlziTWM2OD1yLkG1OFU5KM7:TR?= NH\TblhUSU6JRWK=
K5 NX3iSo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHHfoMzUUN3ME2wMlE3PDh7IN88US=> MoHjV2FPT0WU
KINGS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMU[2OlYh|ryP MnGwV2FPT0WU
SF268 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEntVWdKSzVyPUCuNVc1ODRizszN MUTTRW5ITVJ?
PF-382 NX;EUIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\Ob2lEPTB;MD6xO|Y4QCEQvF2= NXLtfmhyW0GQR1XS
SH-4 M1;qWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ewVWlEPTB;MD6xPFQyOyEQvF2= MVfTRW5ITVJ?
NALM-6 NGDWVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TkNWlEPTB;MD6xPVI6PSEQvF2= NHL2OHhUSU6JRWK=
CP66-MEL NIP4VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUm1N|Eh|ryP NWPTPVdoW0GQR1XS
697 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHwTWM2OD1yLkG5PVg4KM7:TR?= MXjTRW5ITVJ?
CP67-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\3U3N{UUN3ME2wMlIxPDh6IN88US=> M2rO[HNCVkeHUh?=
DSH1 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHrTWM2OD1yLkK0NFAyKM7:TR?= MXvTRW5ITVJ?
HCE-4 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD1yLkK2OFM6KM7:TR?= NVL4UHNWW0GQR1XS
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPYSnFuUUN3ME2wMlI5PTN5IN88US=> MXvTRW5ITVJ?
BL-41 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHkTWM2OD1yLkK5NVI{KM7:TR?= NIi0W41USU6JRWK=
HUTU-80 NGrtbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PiemlEPTB;MD6zNVQzKM7:TR?= NVrFTYtFW0GQR1XS
LOXIMVI M{W1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfNTWM2OD1yLkOxOVA{KM7:TR?= NHu5UFNUSU6JRWK=
no-10 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;LcWlEPTB;MD6zNVk{OSEQvF2= NGjqVpJUSU6JRWK=
KARPAS-422 NUjjXZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD1yLkOzPVk4KM7:TR?= MYXTRW5ITVJ?
SW684 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\uNWlEPTB;MD6zOFk5KM7:TR?= M1L2RXNCVkeHUh?=
SF126 NYjZN4xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHSI1KSzVyPUCuN|U1OSEQvF2= MWHTRW5ITVJ?
D-263MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnuU2JKSzVyPUCuN|YzOjRizszN NF7wUnZUSU6JRWK=
OVCAR-4 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[3TWM2OD1yLkO3OFM{KM7:TR?= MU\TRW5ITVJ?
BB49-HNC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LZZmlEPTB;MD6zPFU6QSEQvF2= NYjqPJhyW0GQR1XS
ONS-76 NXfINW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNdWlEPTB;MD60Nlk2OSEQvF2= NVPHT4Q{W0GQR1XS
MZ7-mel MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj0TWM2OD1yLkS3PVEyKM7:TR?= MkfTV2FPT0WU
RCC10RGB M4Kw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jDSWlEPTB;MD60PVEyKM7:TR?= M1ewTnNCVkeHUh?=
BOKU MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknkTWM2OD1yLkS5NVM{KM7:TR?= MmnRV2FPT0WU
no-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwNUCyNlgh|ryP NELVWXBUSU6JRWK=
IST-SL2 NEHNOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjG[JBnUUN3ME2wMlUxOzB{IN88US=> NIPV[ZRUSU6JRWK=
RKO NV[1W2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nUNmlEPTB;MD61Nlk3PiEQvF2= NXL6dpdZW0GQR1XS
HT-144 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNUO2NFkh|ryP M3P5NXNCVkeHUh?=
NCI-H446 NVfJTWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nPe2lEPTB;MD62Nlc3KM7:TR?= NXvoO3h1W0GQR1XS
QIMR-WIL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\XOGxKUUN3ME2wMlcxPjJ7IN88US=> MVTTRW5ITVJ?
MHH-PREB-1 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHPTWM2OD1yLke0OFY6KM7:TR?= NHTyc2FUSU6JRWK=
EW-16 NEHyN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwN{[xO|gh|ryP NV:wVIZ4W0GQR1XS
EW-24 M2PPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwN{ixOlUh|ryP MkPCV2FPT0WU
LB373-MEL-D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwOEK1NFgh|ryP MW\TRW5ITVJ?
TE-9 M2e0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfNcG9xUUN3ME2wMlg4PTN{IN88US=> MX7TRW5ITVJ?
A3-KAW MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHhU4VKSzVyPUCuPVg1PTJizszN MnjsV2FPT0WU
A101D M4H0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxW4F7UUN3ME2xMlA{ODR|IN88US=> NVT0TXB[W0GQR1XS
OCUB-M MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMES0NVIh|ryP NX3hZZZJW0GQR1XS
ES4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\YOmlEPTB;MT6wOVE1PSEQvF2= NIjTUXhUSU6JRWK=
TE-6 NX71V414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojmTWM2OD1zLkKxNlI3KM7:TR?= MW\TRW5ITVJ?
D-502MG MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDyTWM2OD1zLkKzN|c3KM7:TR?= M1HrTnNCVkeHUh?=
KNS-42 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCbWlEPTB;MT6yOFQyOiEQvF2= NF\rcWJUSU6JRWK=
SNU-C2B NFrDV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjmcZRyUUN3ME2xMlMxPTh7IN88US=> M4rR[3NCVkeHUh?=
NCI-H1838 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Ed2lEPTB;MT6zNFc{OyEQvF2= MVXTRW5ITVJ?
NKM-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M373dWlEPTB;MT6zNFg2QSEQvF2= NFHPcFhUSU6JRWK=
GI-1 NEnkT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXvWoJKSzVyPUGuN|YzOiEQvF2= NEnHV4RUSU6JRWK=
NB5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PV[WlEPTB;MT6zPVgzPyEQvF2= NVjyVFZMW0GQR1XS
CAS-1 NXXxbYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLlWFFZUUN3ME2xMlQxQTl{IN88US=> Mnv1V2FPT0WU
HCE-T NWjaS297T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwNU[3NVQh|ryP MkfMV2FPT0WU
SBC-1 M1Kx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;3SGlEPTB;MT61O|k5PCEQvF2= NWjqT44{W0GQR1XS
JiyoyeP-2003 NELPeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojkTWM2OD1zLkezOFY3KM7:TR?= M1z5OHNCVkeHUh?=
TE-5 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\YSZhKSzVyPUGuO|kyOzlizszN M{D6[3NCVkeHUh?=
CAN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYTWM2OD1zLkiyNlUzKM7:TR?= NXvy[255W0GQR1XS
SK-UT-1 NXfrR4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPaVFJKSzVyPUKuNVY3QTNizszN Mme5V2FPT0WU
JVM-2 NGmwe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6cGlEPTB;Mj6zOlI5PCEQvF2= MUHTRW5ITVJ?
LB771-HNC MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwNUe1OVEh|ryP M{\0NHNCVkeHUh?=
NCCIT NITGPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\keWlEPTB;Mj64OlYyPiEQvF2= MWPTRW5ITVJ?
NCI-H2126 NY[w[WNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\LTWM2OD1{Lki3OVUzKM7:TR?= MlvkV2FPT0WU
Calu-6 M3;PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M163UmlEPTB;Mz6wOVc1OSEQvF2= NULTUWx{W0GQR1XS
SK-LMS-1 NInUb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPjTWM2OD1|LkGxPFg3KM7:TR?= MVfTRW5ITVJ?
ARH-77 M3;CWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DtU2lEPTB;Mz60OlkyPSEQvF2= NEHCNGFUSU6JRWK=
NB17 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHENGhqUUN3ME2zMlY{QDR5IN88US=> MorMV2FPT0WU
A253 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL4eVJKSzVyPUOuO|MzPDZizszN M1nQVHNCVkeHUh?=
OPM-2 M4LIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HzOWlEPTB;ND6yO|Y5PSEQvF2= NWrEeWZ2W0GQR1XS
MV-4-11 NHnidplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLFN3dKSzVyPUSuN|Y1PTRizszN MoLxV2FPT0WU
SR M1;Hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwNEm5OVQh|ryP NWDzVGZFW0GQR1XS
KG-1 NHrBSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YUmlEPTB;ND62NFg1PSEQvF2= M12xOHNCVkeHUh?=
OCI-AML2 M4SxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOw[WZKSzVyPUWuPFYyPTRizszN MWfTRW5ITVJ?
D-247MG M3jHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD14LkGyOVE6KM7:TR?= MlXYV2FPT0WU
DJM-1 M1\CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3sb|FKSzVyPU[uOFg2PThizszN MYXTRW5ITVJ?
RPMI-6666 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjSbYdKSzVyPUeuNlcxPjdizszN NInlR4RUSU6JRWK=
KARPAS-45 NGP0XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW1TWM2OD15LkWxOlcyKM7:TR?= M13BOnNCVkeHUh?=
LP-1 NEH4TXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTdwNUS3PFIh|ryP MXjTRW5ITVJ?
RS4-11 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LmNGlEPTB;Nz62OVc5PyEQvF2= NInmTnpUSU6JRWK=
DU-4475 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTMbndKSzVyPUiuNlE3PTJizszN NV3UdY16W0GQR1XS
MONO-MAC-6 NXjxRZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRThwMkewOlYh|ryP NEPkeWVUSU6JRWK=
NCI-SNU-16 NXu1e5l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwNU[xNlgh|ryP NFPhV2hUSU6JRWK=
SJSA-1 NUHnbHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S2cGlEPTB;OD63NlgxPSEQvF2= MmXLV2FPT0WU
MMAC-SF MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPZTWM2OD16Lke5N|A4KM7:TR?= MnvGV2FPT0WU
SK-NEP-1 NHPQd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO0O|FKSzVyPUiuPFkyPTVizszN NEjGcm5USU6JRWK=
J-RT3-T3-5 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRThwOU[1Nlkh|ryP NH7pO|VUSU6JRWK=
SKM-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS5[FJKSzVyPUmuNFE4OzRizszN M2r1[3NCVkeHUh?=
LB2241-RCC Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LvZmlEPTB;OT6wNlAyOiEQvF2= M4Llc3NCVkeHUh?=
SIG-M5 M2G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnqWph6UUN3ME25MlAzPDl|IN88US=> MU\TRW5ITVJ?
EVSA-T NFzObndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrO[XFKSzVyPUmuNlc4QTNizszN NV64VmZSW0GQR1XS
GT3TKB M1m1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5R2NKSzVyPUmuN|U2PDZizszN M1y1e3NCVkeHUh?=
NB6 NYm3flMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzM[XJKSzVyPUmuPVIzPTlizszN M125dHNCVkeHUh?=
EHEB MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jyfmlEPTB;MUCuNFY2PiEQvF2= M3HZZXNCVkeHUh?=
HEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnUTYFKSzVyPUGwMlQ4PzZizszN Mmi3V2FPT0WU
ALL-PO NHy0OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe3cHpKSzVyPUGwMlc6OzhizszN M{i3eHNCVkeHUh?=
TGW NEH1RoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFzLkK4Nlgh|ryP MlXBV2FPT0WU
BC-3 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi4eVdmUUN3ME2xNk4yOTN6IN88US=> M3vG[3NCVkeHUh?=
IA-LM Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLFS3dKSzVyPUGyMlQ1PDVizszN M{W2NHNCVkeHUh?=
UACC-257 NHrFdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wTWM2OD1zMj65NVk5KM7:TR?= MWjTRW5ITVJ?
KP-N-YS Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{LkmyPFMh|ryP MnS3V2FPT0WU
Raji NHqzcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ZS5RKSzVyPUGzMlc1QTdizszN M{L4TnNCVkeHUh?=
SF539 M1L6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rDUmlEPTB;MUOuPFU2PyEQvF2= MWnTRW5ITVJ?
DMS-153 NUXQfnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL6TWM2OD1zND6wNFI5KM7:TR?= NH2yNllUSU6JRWK=
L-540 NYDLe2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF3LkC2O|Ih|ryP M2DWWnNCVkeHUh?=
MN-60 NH3kbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF3LkG5O|kh|ryP MVHTRW5ITVJ?
RPMI-8866 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP3TWM2OD1zNz60OFU1KM7:TR?= Mn\mV2FPT0WU
NCI-H510A NWTkS4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33yPWlEPTB;MUmuN|k4OyEQvF2= MYDTRW5ITVJ?
NB13 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ld3lMUUN3ME2xPU41QDd5IN88US=> M{jZcHNCVkeHUh?=
HAL-01 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2PY9KSzVyPUG5Mlc2PDNizszN MmLrV2FPT0WU
NCI-H720 NH;XW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjJTWM2OD1{MD6yO|M{KM7:TR?= MlrSV2FPT0WU
REH MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfKTWM2OD1{MD62N|U4KM7:TR?= M33UWXNCVkeHUh?=
KNS-81-FD M4\hXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnGNWZKSzVyPUKzMlE1PiEQvF2= MV;TRW5ITVJ?
HC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ2LkW1OVEh|ryP MkLDV2FPT0WU
NCI-H2141 NV;iZnVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPTWM2OD1{ND63O|U1KM7:TR?= NIC3eY5USU6JRWK=
MOLT-4 NYnVSWVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XKRmlEPTB;Mk[uOlc2OyEQvF2= M1vob3NCVkeHUh?=
OMC-1 M{HoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ5LkG0NlIh|ryP NXzqOIZrW0GQR1XS
LC-1F NUnEUGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ5LkOyOFUh|ryP M3v3RXNCVkeHUh?=
NCI-H1304 NH\5e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ6LkG2Nlgh|ryP MkLvV2FPT0WU
BC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ6Lk[1NUDPxE1? NUSxe3YyW0GQR1XS
NCI-H64 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f5U2lEPTB;MkmuOlI2OyEQvF2= MnTWV2FPT0WU
MOLT-16 NEGyb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[4VolsUUN3ME2yPU43Ojl{IN88US=> M4XkVXNCVkeHUh?=
U-87-MG M3W0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\KTWM2OD1|MD63OlYh|ryP MVnTRW5ITVJ?
GAK NYH4U4hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG5T4RmUUN3ME2zNU4zPjh4IN88US=> NXr2SG9KW0GQR1XS
ES8 NGnrU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm5TWM2OD1|Mj6xNlUzKM7:TR?= MYXTRW5ITVJ?
HCC1599 NYK0NW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\leGlEPTB;M{KuN|MzPSEQvF2= NUjnSFV6W0GQR1XS
EB-3 M1L3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr2NZJKSzVyPUO0MlMyOTdizszN MYLTRW5ITVJ?
HCC1187 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PiXGlEPTB;M{WuPFA2OiEQvF2= NGHXS2JUSU6JRWK=
SK-PN-DW MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLZWlEPTB;M{[uNVk1OyEQvF2= M4DyNHNCVkeHUh?=
JVM-3 NV\GUG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\2TWM2OD1|Nz6yN|M5KM7:TR?= M37SO3NCVkeHUh?=
HCC2157 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYXm85UUN3ME2zO{46QTR4IN88US=> MoLjV2FPT0WU
A4-Fuk NYnHc3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDSWlEPTB;M{iuNVAxQSEQvF2= M4nzNnNCVkeHUh?=
COR-L279 NUXYZ3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PF[2lEPTB;NECuNlg2OSEQvF2= NYPUWmF5W0GQR1XS
DEL NIPCWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zEUmlEPTB;NEGuPVA5PiEQvF2= MVvTRW5ITVJ?
NCI-H1395 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnPTWM2OD12Mj6wNVY{KM7:TR?= MofEV2FPT0WU
MHH-NB-11 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\VcIFKSzVyPUSzMlA5OThizszN NIO4fmRUSU6JRWK=
NCI-H2107 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fK[WlEPTB;NEOuOFg1PiEQvF2= NHjEZodUSU6JRWK=
NEC8 NV21Xm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnLRWFKSzVyPUS0MlM{PiEQvF2= NWe3TZRbW0GQR1XS
COLO-684 M1;5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zYUWlEPTB;NE[uNlI2QCEQvF2= MlnvV2FPT0WU
LS-411N MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO5TWM2OD12OD60O|Q5KM7:TR?= MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2
NCT02011945 Active not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb February 7 2014 Phase 1
NCT02389309 Recruiting Solid Tumors M.D. Anderson Cancer Center October 5 2015 Phase 1
NCT02744768 Recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto May 31 2017 Phase 2
NCT01999985 Active not recruiting Lung Cancer|Non-small Cell Lung Cancer (NSCLC) H. Lee Moffitt Cancer Center and Research Institute|Boehringer Ingelheim|Bristol-Myers Squibb December 31 2013 Phase 1
NCT01660971 Active not recruiting Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 National Cancer Institute (NCI) July 30 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID